XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focused on its New Strategic Direction on March 16, 2017 Mar 14, 2017 7:00am EDT
XOMA to Present New Strategic Initiatives at the Cowen and Company 37th Annual Health Care Conference Feb 28, 2017 7:00am EST
XOMA Announces Pricing of $25 Million Registered Offering of Common Stock and Convertible Preferred Stock Feb 13, 2017 7:00am EST
XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery Jan 31, 2017 4:00pm EST
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update Dec 21, 2016 5:00pm EST
New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting Nov 08, 2016 9:00am EST
XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism Oct 19, 2016 9:00am EDT
